Larger natural history studies are needed that measure disease progression together with whole-brain and region-specific radiotracer binding, including in genetically homogeneous patient cohorts, to confirm the validity of TSPO PET as a reliable biomarker for interventional studies in thus far incurable mitochondrial diseases. Here, TSPO is linked to inborn mitochondrial metabolism disorder.